Clinical Trial Update: Effectiveness of Brolucizumab in Pre-treated Patients With nAMD in the Real-world Setting

View source ↗

Summary

A terminated real-world trial evaluating the effectiveness of brolucizumab in pre-treated patients with neovascular age-related macular degeneration.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• Brolucizumab (Beovu) (brolucizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Neovascular Age-related Macular Degeneration | Status: TERMINATED